



Correlation between HIF-1 α and BCL2 Expression and Tumor Behavior in Locally Advanced Head and Neck Squamous Cell Carcinoma

Thesis

*Submitted for Partial Fulfillment of MD Degree in clinical
Oncology and Nuclear Medicine*

Presented by

Lamiaa Moustafa Abdel Megied Mohamed Ahmed
M.B., B. Ch, M.Sc

Supervised by

Prof. Dr./ Zeinab Mohammed Abdel-Hafeez Elsayed

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr./ Mohammad Sabry Elkady

*Assis. Prof. of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr./ Waleed Abd Elmonem Biomy

*Assis. Prof. of clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr./ Mai Mohamed Ali Ezz El Din

*Assis. Prof. of clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Zeinab Mohammed Abdel-Hafeez Elsayed**, Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Mohammad Sabry Elkady**, Assistant Prof. of Clinical Oncology and Nuclear Medicine Faculty of medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Waleed Abdelmonem Biomy**, Assistant Prof. of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Mai Mohamed Ali Ezz El Din**, Assistant Prof. of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this work.*

*I would be forever in debt to **Dr. Nashwa El Khazragy**, Consultant of Clinical Pathology, Ain Shams University for her tremendous effort and dedication throughout this work.*

*Last but never the least, I would like to thank **my family: my mother, my father, my husband and my little angel**, without your continuous help, encouragement, support and love, I would have never been able to accomplish anything. You always make me want to be a better person.*

Lamiaa Moustafa Abdel Megied

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	9
Introduction	1
Aim of the Work.....	4
Review of Literature	
📖 Epidemiology	5
📖 Diagnosis and Staging Evaluation	10
📖 Molecular Biology	25
Patients and Methods	53
Results	69
Discussion	96
Summary and Conclusion	105
Recommendations	107
References	108
Appendix	132
Arbic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	T staging of lip and oral cavity	20
Table (2):	T staging of oropharynx	20
Table (3):	T staging of hypopharynx	21
Table (4):	T staging of larynx	22
Table (5):	Regional lymph nodes staging and distant metastasis.....	23
Table (6):	Stage grouping of HNSCC rather than nasopharynx	24
Table (7):	Demographic Characteristics and Clinical Data of the studied Subjects	72
Table (8):	Comparative statistics of HIF-1 α and BCL2 among various studied groups (HNSCC/ healthy control) using Kruskal-Wallis test.....	73
Table (9):	Comparative Statistics between different HNSCC subgroups for expression of HIF- α and BCL-2 using Mann-Witney Test	75
Table (10):	Comparative analysis of expression values of HIF-1 α and BCL-2 between the different stages of HNSCC patients (by Kruskal-Wallis test value).....	76
Table (11):	Spearman's correlation analysis of between measured parameters and OS and PFS among the HNSCC patient.....	78
Table (12):	Comparative analysis of OS and PFS between the high and low HIF-1 α expressions among the HNSCC patients	80

List of Tables (cont...)

Table No.	Title	Page No.
Table (13):	Comparative analysis of OS and PFS between the high and low BCL-2 expressions among the HNSCC patients	83
Table (14):	COX regression analysis for factors affecting OS and PFS in HNC patients (months)	85

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Mechanism of action of the human papillomavirus (HPV) on cell cycle regulation....	29
Figure (2):	EGFR activation pathways	33
Figure (3):	Schematic depicting HIF pathway under normoxic and hypoxic conditions	39
Figure (4):	Schematic overview of the Bcl-2 family of proteins	51
Figure (5):	Expression levels of HIF-1 α and BCL-2 among different studied groups.....	74
Figure (6):	Expression levels of HIF-1 α and BCL-2 among different HNSCC T stage subgroups.	77
Figure (7):	Scatter plot explaining the correlation between expression values of HIF-1 α and BCL-2 in HNSCC patients.....	79
Figure (8):	Kaplan–Meier survival curve for the PFS according to HIF-1 α	81
Figure (9):	Kaplan–Meier survival curve for the OS according to HIF-1 α	82
Figure (10):	Kaplan–Meier survival curve for the PFS with BCL-2	83
Figure (11):	Kaplan–Meier survival curve for the OS with BCL-2	84
Figure (12):	Kaplan–Meier survival curves for the PFS according to age.	86
Figure (13):	Kaplan–Meier survival curves for the OS according to age	87

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (14):	Kaplan–Meier survival curves for the PFS according to gender	87
Figure (15):	Kaplan–Meier survival curves for the OS according to gender.	88
Figure (16):	Kaplan–Meier survival curves for the PFS according to smoking.	88
Figure (17):	Kaplan–Meier survival curves for the OS according to smoking.	89
Figure (18):	Kaplan–Meier survival curves for the PFS according to tumor site.....	89
Figure (19):	Kaplan–Meier survival curves for the OS according to tumor site.....	90
Figure (20):	Kaplan–Meier survival curves for the PFS according to tumor stage.	90
Figure (21):	Kaplan–Meier survival curves for the OS according to tumor stage.	91
Figure (22):	Kaplan–Meier survival curves for the PFS according to T stage.	92
Figure (23):	Kaplan–Meier survival curves for the OS according to T stage.	92
Figure (24):	Kaplan–Meier survival curves for the PFS according to nodal infiltration.	93
Figure (25):	Kaplan–Meier survival curves for the OS according to nodal infiltration.	93
Figure (26):	Kaplan–Meier survival curves for the PFS according to response to treatment.	94
Figure (27):	Kaplan–Meier survival curves for the OS according to response to treatment.	95

List of Abbreviations

Abb.	Full term
<i>17-AAG</i>	<i>17-N-Allylamino-17-demethoxy geldanamycin</i>
<i>17-DMAG</i>	<i>17-dimethylaminoethylamino-17-demethoxygeldanamycin</i>
<i>2ME2</i>	<i>2-Methoxyestradiol</i>
<i>ADH</i>	<i>Alcohol Dehydrogenase</i>
<i>Akt</i>	<i>Serine / Threonine-Specific Protein Kinase</i>
<i>ALDH</i>	<i>Aldehyde Dehydrogenase</i>
<i>ARF</i>	<i>Alternative Reading Frame</i>
<i>ATP</i>	<i>Adenosine Triphosphate</i>
<i>BCL2</i>	<i>B-cell Lymphoma 2</i>
<i>BH3</i>	<i>Bcl-2 Homology 3</i>
<i>CAIX</i>	<i>Carbonic Anhydrase 9</i>
<i>CT</i>	<i>Computed Tomography</i>
<i>CTGF</i>	<i>Connective Tissue Growth Factor</i>
<i>DAHANCA</i>	<i>Danish Head and Neck Cancer Group</i>
<i>DHFR</i>	<i>Dihydrofolate Reductase</i>
<i>DNA</i>	<i>Deoxyribonucleic Acid</i>
<i>DOI</i>	<i>Depth of Invasion</i>
<i>E6-AP</i>	<i>E6-Associated Protein</i>
<i>EF5</i>	<i>([2-(2-nitro-1H-imidazol-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamine]</i>
<i>EGFR</i>	<i>Epidermal Growth Factor Receptor</i>
<i>ErbB</i>	<i>Erythroblastic Leukemia Viral Oncogene Homolog 2</i>
<i>EORTC</i>	<i>European Organisation for Research and Treatment of Cancer</i>
<i>FAZA</i>	<i>Fluoroazomycinarabinofuranoside</i>
<i>FDG</i>	<i>Fluoro-deoxyglucose</i>
<i>FISMO</i>	<i>Fluorine 18-Fluoromisonidazole</i>
<i>GLUTs</i>	<i>Glucose Transporters</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>Grb2</i>	<i>Growth Factor Receptor-Bound Protein 2</i>
<i>GTP</i>	<i>Guanine Triphosphate</i>
<i>Gy</i>	<i>Gray</i>
<i>HBO</i>	<i>Hyperbaric Oxygen</i>
<i>HDAC</i>	<i>Histone Deacetylase</i>
<i>HER</i>	<i>Human Epidermal Growth Factor Receptor</i>
<i>HIF1α</i>	<i>Hypoxia-Inducible Factor 1 Alpha</i>
<i>HIG-2</i>	<i>Hypoxia-Inducible Gene-2</i>
<i>HNC</i>	<i>Head and Neck Cancer</i>
<i>HNSCC</i>	<i>Head and Neck Squamous Cell Carcinoma</i>
<i>HPV</i>	<i>Human Papilloma Virus</i>
<i>HREs</i>	<i>Hypoxia Response Elements</i>
<i>Hsp90</i>	<i>Heat Shock Protein 90</i>
<i>IGF-1R</i>	<i>Insulin-Like Growth Factor-1 Receptor</i>
<i>IHC</i>	<i>Immunohistochemistry</i>
<i>IKK-b</i>	<i>IkappaB Kinase Beta</i>
<i>IL</i>	<i>Interleukin</i>
<i>INF</i>	<i>Interferon</i>
<i>IQR</i>	<i>Interquartile ratio</i>
<i>JAK</i>	<i>Janus Kinase</i>
<i>LOX</i>	<i>Lysyl Oxidase</i>
<i>MAPK</i>	<i>Mitogen-Activated Protein Kinases</i>
<i>MDM2</i>	<i>Mouse Double Minute 2 Homolog</i>
<i>mm Hg</i>	<i>Millimeter Mercury</i>
<i>MOM</i>	<i>Mitochondrial Outer Membrane</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>mTOR</i>	<i>Mammalian Target of Rapamycin</i>
<i>NRP-1</i>	<i>Neuropilins</i>
<i>NRP-2</i>	<i>Neuropilins</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>OPN</i>	<i>Osteopontin</i>
<i>OPSCC</i>	<i>Oropharyngeal Squamous Cell Carcinoma</i>
<i>OS</i>	<i>Overall Survival</i>
<i>p53</i>	<i>Protein p53</i>
<i>p63</i>	<i>Protein p63</i>
<i>p73</i>	<i>Protein p73</i>
<i>PDGFR</i>	<i>Platelet-Derived Growth Factor Receptor</i>
<i>PDK1</i>	<i>Pyruvate Dehydrogenase Kinase</i>
<i>PEITC</i>	<i>2-Phenethyl Isothiocyanate</i>
<i>PET-CT</i>	<i>Positron emission tomography -Computed Tomography</i>
<i>PFS</i>	<i>Progression Free Survival</i>
<i>PHD</i>	<i>Prolyl Hydroxylase Domain</i>
<i>PI3K</i>	<i>Phosphatidylinositol 3-Kinase</i>
<i>PIP2</i>	<i>Phosphorylation of Phosphatidylinositol 4, 5-Diphosphate</i>
<i>PIP3</i>	<i>Phosphorylation of Phosphatidylinositol 3, 4, 5-triphosphate</i>
<i>PlGF</i>	<i>Placental Growth Factor</i>
<i>PO2</i>	<i>Oxygen Pressure</i>
<i>pRb</i>	<i>Retinoblastoma Protein</i>
<i>R</i>	<i>Correlation Coefficient</i>
<i>Raf</i>	<i>Rapidly Accelerated Fibrosarcoma</i>
<i>RAS</i>	<i>Human Homologs of Murine Sarcoma Virus Oncogenes</i>
<i>RNA</i>	<i>Ribonucleic Acid</i>
<i>ROS</i>	<i>Reactive Oxygen Species</i>
<i>RQ</i>	<i>Relative Quantitation of gene expression in relation to housekeeper gene.</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>RR</i>	<i>Relative Risk</i>
<i>RT</i>	<i>Radiotherapy</i>
<i>RTKs</i>	<i>Receptor Tyrosine Kinases</i>
<i>RTOG</i>	<i>Radiation Therapy Oncology Group</i>
<i>SCC</i>	<i>Squamous Cell Carcinoma</i>
<i>SD</i>	<i>Stable Disease</i>
<i>STAT</i>	<i>Signal Transducer and Activator of Transcription</i>
<i>STIR</i>	<i>Short Tau Inversion-Recovery</i>
<i>TGF-α</i>	<i>Transforming Growth Factor-Alpha</i>
<i>TP53</i>	<i>Tumor Protein p53</i>
<i>TPF</i>	<i>Docetaxel, Cisplatin and 5 Flououracil</i>
<i>TPZ</i>	<i>Tirapazamine</i>
<i>TSA</i>	<i>Trichostatin A</i>
<i>VEGF</i>	<i>Vascular Endothelial Growth Factor</i>
<i>VGFR</i>	<i>Vascular Endothelial Growth Factor Receptor</i>
<i>VHL</i>	<i>Von Hippel–Lindau</i>

ABSTRACT

Background: Head and neck cancer represents more than 550,000 cases annually. It accounts for 380,000 deaths every year. Despite aggressive treatment, only 35% to 55% of patients who present with locally advanced HNC cancer remain alive and free of disease 3 years after standard curative treatment. Thirty percent to 40% of patients develop locoregional recurrences, and distant metastases occur in 20% to 30%. Most recurrences appear quickly within 2 years of initial treatment and an additional 10% of patients will have evidence of distant metastases at the time of first presentation.

Purpose: To retrospectively determine the prognostic effect of T stage in locally advanced head and neck cancer.

Methods: This study retrospectively analyzed 40 patients diagnosed with locally advanced head and neck cancer. Patients were diagnosed by a tissue biopsy and they were staged by endoscope and CT neck or MRI neck with contrast. They received their treatment and were followed up every 3 months by CTs.

Results: We found a statistically significant correlation between T stage and both PFS and OS (95%, CI 1.00 – 3.10, $p=0.04$ and 95% CI 1.01 – 2.65, $p=0.05$ respectively).

Conclusion: This study confirmed that the T stage of the tumor is an important prognostic factor in locally advanced head and neck cancer.

Keywords: Locally advanced head and neck cancer. T stage. Prognosis.

INTRODUCTION

Across the world, head and neck cancer (HNC) represents more than 550,000 cases and 380,000 deaths every year. Males are affected more than females with a ratio ranging from 2:1 to 4:1 (*Fitzmaurice et al., 2017*).

Previous hospital-based studies from Egypt showed that HNC constitutes about 17-20% of all malignancies. A study describing the epidemiology of HNC in Egypt using data from the only population-based cancer registry, a higher incidence of HNC among males than females and higher incidence in urban than rural populations were documented. Overall, the incidence of HNC was highest in the 70+ age group in both males and females (*Attar, 2010*).

Squamous cell carcinomas represent nearly 90% of all head and neck cancers, arising mainly in the oral cavity but also occurring in the nasal cavity, pharynx and larynx (*Mehanna et al., 2010*).

The patterns of local invasion and distant spread of head and neck squamous cell carcinoma (HNSCC) differ depending on the intrinsic properties of individual tumors themselves but these events are also strongly influenced by properties of the local tumor microenvironment. For example, the presence of stromal cells, such as cancer associated fibroblasts and of recruited inflammatory cells, markedly influences tumor behavior (*Wheeler et al., 2014*).

Hypoxia is also considered a major microenvironmental influence and HNSCC, like many solid tumors, develops areas of hypoxia when the blood supply becomes limited due to tumor growth, vascular disturbances or metabolic changes (*Overgaard, 2011*).

Efficacy of radiation treatment relies on DNA damage, either via direct damage of DNA by ionizing radiation or by free radicals that are generated and subsequently react with DNA, causing damage. Oxygen free radicals are highly reactive and are the primary source of radiation-induced DNA damage, and oxygen is, therefore, a potent radiosensitizer. Hypoxic HNSCC, measured by pretreatment tumor PO₂, have been shown to be significantly more likely to persist or recur locoregionally (*Nordsmark and Overgaard, 2000*).

Hypoxia-inducible factor 1 α (HIF1- α) is an intracellular transcription factor that undergoes degradation under well-oxygenated conditions but is stabilized under hypoxic conditions. When HIF1- α is stabilized, it regulates the expression of proangiogenic genes, such as vascular endothelial growth factor (VEGF) (*Koukourakis et al., 2002*).

In a study of 75 HNSCC specimens, overexpression of HIF1- α , assessed by immunohistochemistry (IHC) was associated with locally aggressive behavior (*Nordsmark et al., 2007*).